Aradigm Receives FDA Clearance For Clinical Trial Of Inhaled Liposomal Ciprofloxacin In Pediatric Patients With Cystic Fibrosis
Originally posted in Cystic Fibrosis News From Medical News Today
Aradigm Corporation (OTCBB:ARDM) (the “Company”) announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application…
No Comments
RSS feed for comments on this post.
by Raelene
